KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

Atul Malhotra, Ronald Grunstein, Ali Azarbarzin, Scott Sands, Virend K Somers, Louis J Aronne, Ania M Jastreboff, Jitong Lou, Sujatro Chakladar, Julia P Dunn, Mathijs C Bunck, Josef Bednarik

Nat Med 32(2) 653-659

PMID41540105
PMCIDPMC12920140
DOI10.1038/s41591-025-04071-1
发表日期2026-01-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图。
摘要

摘要

Obstructive sleep apnea (OSA) is associated with obesity and cardiovascular risk. The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide. Here we report prespecified analysis of cardiometabolic risk measures in SURMOUNT-OSA. Post hoc analyses include changes in a homeostatic model assessment for insulin resistance and mediation analysis to determine the proportion of observed changes attributable to reductions in body weight, apnea-hypopnea index and sleep apnea-specific hypoxic burden. In both study 1 and study 2 of SURMOUNT-OSA, tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo. Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides. The combination of changes in weight and OSA metrics, as well as weight alone, had a significant mediation effect on systolic blood pressure, but there was no significant mediation effect of weight or OSA metrics observed on diastolic blood pressure. Based on the mediation analysis, treating both sleep-disordered breathing and obesity is likely required to optimize the treatment effect on cardiometabolic benefits for patients with moderate-to-severe OSA and obesity. The ClinicalTrials.gov registration number for this study is NCT05412004 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design flowchart. The data from a previously published study protocol 13 . HbA1c, hemoglobin A1C; MTD, maximum tolerated dose; TZP, tirzepatide. Source data
非 KM Figure
Fig. 2Proportion of tirzepatide effect on cardiometabolic risk measures mediated by body weight, AHI and SASHB. The data are presented as model-based estimate for the mean (95% CI). Statistical analyses were performed using the bootstrap method. All hypothesis testing was conducted using a two-sided framework, and the results are summarized with 95% CIs, which were derived from the corresponding 2.5th and 97.5th percentiles of the bootstrapped estimates (HOMA-IR n = 336; non-HDL-C n = 341; HDL-C n = 342; triglycerides n = 341; hsCRP n = 342; DBP n = 364; SBP n = 364). * P < 0.05, ** P < 0.01, *** P < 0.001 representing significant proportion mediated.
非 KM Figure